PharmaEssentia Corporation Stock Deutsche Boerse AG
Stocks
8Z1
US7169722037
Biotechnology & Medical Research
|
Market Closed -
Deutsche Boerse AG
03:34:57 2026-03-09 EDT
|
5-day change | 1st Jan Change | ||
| 15.50 EUR | -.--% |
|
+11.00% | - |
| 08-31 | PharmaEssentia Gets US FDA's Approval for Essential Thrombocythemia Treament Drug; Shares Sink 10% | MT |
| 08-28 | US FDA approves Takeda, Protagonist's drug for rare blood cancer | RE |
| Market Cap | 541B 17.03B 14.69B 13.84B 12.61B 23.57B 1,608B 23.74B 164B 63.58B 822B 63.94B 62.54B 2,701B | P/E 2026 * |
49.2x | P/E 2027 * | 31x |
|---|---|---|---|---|---|
| Enterprise Value | 514B 16.19B 13.97B 13.16B 11.99B 22.41B 1,530B 22.58B 156B 60.46B 782B 60.8B 59.47B 2,569B | EV / Sales 2026 * |
18.2x | EV / Sales 2027 * | 12.6x |
| Free-Float |
77.98% | Yield 2026 * |
0.31% | Yield 2027 * | 0.18% |
| 1 week | +11.00% | ||
| Current month | +11.00% | ||
| 1 month | +11.00% | ||
| 3 months | +11.00% | ||
| 6 months | +11.00% |
| Current year | 13.96 |  | 15.5 |
| 1 year | 13.96 | | 15.5 |
| 3 years | 13.96 | | 15.5 |
| 5 years | 13.96 | | 15.5 |
| 10 years | 13.96 | | 15.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
Kuo Chung Lin
CEO | Chief Executive Officer | - | 2016-12-31 |
Hsueh Ling Chang
DFI | Director of Finance/CFO | - | 2015-10-13 |
Cheng Ku Huang
PSD | President | - | 2015-06-24 |
| Director | Title | Age | Since |
|---|---|---|---|
Kuo Chung Lin
BRD | Director/Board Member | - | 2000-05-08 |
Ching-Leou Teng
CHM | Chairman | - | 2012-09-23 |
Cheng Ku Huang
BRD | Director/Board Member | - | 2015-05-28 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | +11.00% | - | - | 17.13B | |
| +1.03% | -3.11% | +39.80% | +94.60% | 68.21B | |
| +1.62% | +2.43% | +48.66% | +88.33% | 64.25B | |
| +4.21% | +2.21% | -6.96% | +459.32% | 26.54B | |
| +1.83% | -8.98% | +3.81% | -14.74% | 25.61B | |
| +1.30% | -0.96% | +32.58% | -17.99% | 19.88B | |
| -0.38% | -12.42% | +224.86% | +373.18% | 17.13B | |
| +0.65% | -5.83% | +1.44% | +544.44% | 14.93B | |
| +2.88% | +3.19% | +56.41% | +157.39% | 14.1B | |
| +1.53% | +6.79% | +24.91% | +195.41% | 12.45B | |
| Average | +1.47% | -3.75% | +47.28% | +208.88% | 29.23B | |
| Weighted average by Cap. | +1.50% | -3.01% | +43.26% | +162.51% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 28.33B 892M 769M 725M 660M 1.23B 84.25B 1.24B 8.58B 3.33B 43.07B 3.35B 3.28B 141B | 40.06B 1.26B 1.09B 1.02B 934M 1.75B 119B 1.76B 12.13B 4.71B 60.91B 4.74B 4.63B 200B |
| Net income | 11.02B 347M 299M 282M 257M 480M 32.78B 484M 3.34B 1.3B 16.76B 1.3B 1.27B 55.05B | 17.69B 557M 480M 453M 412M 771M 52.61B 777M 5.36B 2.08B 26.9B 2.09B 2.05B 88.36B |
| Net Debt | -26.52B -835M -720M -679M -618M -1.16B -78.88B -1.16B -8.03B -3.12B -40.33B -3.14B -3.07B -132B | -34.73B -1.09B -943M -889M -810M -1.51B -103B -1.52B -10.52B -4.08B -52.8B -4.11B -4.02B -173B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 6446 Stock
- 8Z1 Stock
Select your edition
All financial news and data tailored to specific country editions
